Dr Kogularamanan (Rama) Suntharalingam
Lecturer in Bioinorganic Chemistry
Tel: +44 (0)20 7848 2595
Address: Department of Chemistry King's College London Room 115, Britannia House 7 Trinity Street London SE1 1DB
All candidates interested in pursuing PhD, postdoctoral and year abroad (i.e. Erasmus) studies in the Suntharalingam group are encurage to contact Rama directly: email@example.com
We will shortly be advertising for an EPSRC-funded 2-year postdoctoral position. Please contact Rama via email for informal enquiries.
Kogularamanan Suntharalingam obtained his MSci in Chemistry from Imperial College London (UK) in 2008, winning many prizes in the process. Rama's first taste of research came in Prof. Mike Hill's laboratory as an UROP student. He was awarded his PhD in Bioinorganic Chemistry from Imperial College London (UK) in 2012. His PhD research was carried out under the guidance of Prof. Ramon Vilar. He joined Prof. Stephen J. Lippard’s research group at Massachusetts Institute of Technology (MA, USA) and was granted a Misrock Fellowship (Misrock Foundation, Koch Institute for Integrative Cancer Research) in 2012. He was awarded the Dalton Young Researchers Award by the Royal Society of Chemistry in 2014 for his “contributions to the design and development of new metallo-pharmaceuticals and to the understanding of their complex mechanisms of action.” In the same year he began his independent research group at King’s College London (UK) after the award of a Leverhulme Early Career Fellowship. He was named as one of the 175 Faces of Chemistry by the Royal Society of Chemistry in 2016. The following year, he was officially awarded a Lectureship in Bioinorganic Chemistry at King’s College London (UK) and in 2018, he gave a Rising Star in Coordination Chemistry Award Lecture at the 43rd International Conference on Coordination Chemistry. His research group is interested in finding inorganic solutions to unmet biomedical/ bioscience problems.
Research Group: Suntharalingam
Cancer stem cells (CSCs) are a distinct population of tumour cells that have the ability to self-renew, differentiate, and form metastatic tumours. CSCs effectively evade conventional chemotherapy and radiotherapy as these treatments specifically target fast growing cancer cells, and CSCs, due to their stem cell-like properties, divide more slowly. After surviving treatment, CSCs are able to regenerate the original tumour and/or produce invasive cancer cells that are able to colonise distant organs. For these reasons, CSCs are widely thought to be responsible for cancer relapse. Therefore, to provide a durable response and prevent tumour recurrence, chemotherapeutics must have the ability to remove the entire population of cancer cells, including CSCs. Therapeutic strategies capable of selectively killing CSCs and disrupting the microenvironments (niches) supporting these cells are the focus of several research programmes. Potential CSC therapeutic targets such as cell surface markers and various deregulated signalling pathways have been identified, but there is still no clinically approved drug that specifically kills CSCs. Many academia- and pharmaceutical-led studies aimed at developing chemical or biological anti-CSC agents are ongoing. Our group aims to harness the diversity and versatility offered by metals to develop inorganic compounds capable of potently and selectively killing CSCs (over bulk cancer cells and normal non-proliferating cells).
Dr Suntharalingam's Research Portal
The Suntharalingam group aims to use the structural, optical, redox, magnetic, and catalytic diversity offered by metal-containing small molecules to design and develop new generations of metallopharmaceuticals for the treatment of cancer and other diseases. The group also focuses on engineering new nano-material systems to deliver therapeutics to their site(s) of action.
Suntharalingam Research Page
- Munteanu CR, Suntharalingam K*, “Advances in cobalt complexes as anticancer agents” Daltons Transactions 2015, 44 (31), 13796-13808
- Boodram NJ, Mcgregor IJ, Bruno PM, Hemann MT, Suntharalingam K*, “Breast Cancer Stem Cell Potent Copper(II)–Non-Steroidal Anti-Inflammatory Drug Complexes” Angewandte Chemie International Edition, 2016, 55, 2845-2850.
- Lu C, Laws K, Eskandari A, Suntharalingam K*, “A reactive oxygen species-generating, cyclooxygenase-2 inhibiting, cancer stem cell-potent tetranuclear copper(II) cluster” Dalton Transactions, 2017, 46, 12785-12789.
- Laws K, Bineva-Todd G, Eskandari A, Lu C, O'Reilly N, Suntharalingam K*, “A Copper(II)-Phenanthroline Metallopeptide that Targets and Disrupts Mitochondrial Function in Breast Cancer Stem Cells” Angewandte Chemie International Edition, 2018 57, 287-291.
- Eskandari A, Kundu A, Lu C, Ghosh S, Suntharalingam K*, “Synthesis, characterization, and cytotoxic properties of mono- and di-nuclear cobalt(II)-polypyridyl complexes” Dalton Transactions, 2018, 47, 5755-5763.
- Rundstadler TK, Eskandari A, Norman SM, Suntharalingam K*, “Polypyridyl Zinc(II)-Indomethacin Complexes with Potent Anti-Breast Cancer Stem Cell Activity” Molecules, 2018, 23(9), 2253.
- Laws K, Eskandari A, Lu C, Suntharalingam K*, “Highly charged, cytotoxic, cyclometalated iridium(III) complexes as cancer stem cell mitochondriotropics” Chemistry - A European Journal, 2018, DOI: 10.1002/chem.201803521.
- Laws K, Suntharalingam K*, “The next generation of anticancer metallopharmaceuticals: cancer stem cell‐active inorganics” ChemBioChem, 2018, DOI: 10.1002/cbic.201800358.
- Abe DO, Eskandari A, Suntharalingam K*, “Diflunisal-adjoined cobalt(III)-polypyridyl complexes as anti-cancer stem cell agents” Dalton Transactions, 2018, DOI: 10.1039/C8DT03448F.